What is Affymax?
Affymax, Inc. is a company that previously focused on developing drugs aimed at enhancing the treatment of serious and life-threatening conditions within the United States. Founded in 2001 and based in New York, the company's operational scope has been limited, with a primary emphasis on its drug development pipeline.
How much funding has Affymax raised?
Affymax has raised a total of $92.5M across 1 funding round:
Stock Offering
$92.5M
Stock Issuance/Offering (2006): $92.5M, investors not publicly disclosed
What's next for Affymax?
The recent major strategic investment into Affymax signals a potential pivot or a significant push in its drug development initiatives. Given the enterprise-level funding context, this capital infusion is likely intended to accelerate clinical trials, expand research capabilities, or prepare for future commercialization efforts. The company's trajectory will be closely watched as it leverages this financing to advance its therapeutic offerings.
See full Affymax company page
